Genomic Health presents 11 studies demonstrating value of Oncotype DX breast cancer t
 

Genomic Health today announced the presentation of 11 studies with the Oncotype DX breast cancer test at the 14th St. Gallen Breast Cancer Conference in Vienna, Austria. Studies presented include results from a real-life observational study in Ireland demonstrating significant reductions in chemotherapy and resulting cost savings when the test is used in early stage breast cancer.

More...